- Home
- AWH vs ENSC Comparison
AWH vs ENSC Comparison
Compare AWH & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- ENSC
- Stock Information
- Founded
- AWH 1993
- ENSC 2003
- Country
- AWH United States
- ENSC United States
- Employees
- AWH N/A
- ENSC N/A
- Industry
- AWH Medical/Dental Instruments
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- AWH Health Care
- ENSC Health Care
- Exchange
- AWH Nasdaq
- ENSC Nasdaq
- Market Cap
- AWH 10.5M
- ENSC 9.8M
- IPO Year
- AWH N/A
- ENSC N/A
- Fundamental
- Price
- AWH $0.50
- ENSC $7.77
- Analyst Decision
- AWH Buy
- ENSC
- Analyst Count
- AWH 2
- ENSC 0
- Target Price
- AWH $4.40
- ENSC N/A
- AVG Volume (30 Days)
- AWH 100.3K
- ENSC 100.5K
- Earning Date
- AWH 11-14-2024
- ENSC 03-14-2025
- Dividend Yield
- AWH N/A
- ENSC N/A
- EPS Growth
- AWH N/A
- ENSC N/A
- EPS
- AWH N/A
- ENSC N/A
- Revenue
- AWH $8,963,000.00
- ENSC $4,421,404.00
- Revenue This Year
- AWH $11.87
- ENSC $89.78
- Revenue Next Year
- AWH $79.10
- ENSC N/A
- P/E Ratio
- AWH N/A
- ENSC N/A
- Revenue Growth
- AWH N/A
- ENSC 40.41
- 52 Week Low
- AWH $0.38
- ENSC $2.12
- 52 Week High
- AWH $5.65
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- AWH 27.14
- ENSC 50.09
- Support Level
- AWH $0.38
- ENSC $6.75
- Resistance Level
- AWH $0.79
- ENSC $9.57
- Average True Range (ATR)
- AWH 0.07
- ENSC 0.73
- MACD
- AWH -0.02
- ENSC -0.13
- Stochastic Oscillator
- AWH 27.91
- ENSC 36.17
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.